Summary & Overview
HCPCS J0390: Injection, Chloroquine Hydrochloride, up to 250 mg
HCPCS Level II code J0390 denotes an injection of chloroquine hydrochloride, up to 250 mg, used for parenteral administration of the antimalarial and immunomodulatory agent. Nationally, this code matters for accurate identification of injectable chloroquine use across ambulatory and clinic settings, where tracking medication utilization, billing compliance, and coverage determinations intersect with clinical care.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how the code is classified, typical sites of service, and the operational context for billing injectable chloroquine in outpatient and ambulatory settings. The publication outlines benchmarks and common payer considerations for medication billing, summarizes relevant policy updates where applicable, and situates the clinical context for clinicians and billing professionals who encounter parenteral antimalarial therapy.
This summary provides actionable clarity on the code’s clinical identity and administrative uses, helping revenue cycle and clinical staff understand where J0390 fits in medication billing workflows, payer coverage conversations, and reporting structures. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Billing Code Overview
HCPCS Level II code J0390 represents an injection of chloroquine hydrochloride, up to 250 mg. This HCPCS Level II entry denotes a single-dose injectable formulation of the antimalarial and immunomodulatory agent chloroquine hydrochloride.
Service Type: Injectable medication administration
Typical Site of Service: Outpatient clinics, physician offices, and other ambulatory care settings where parenteral medications are administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an outpatient infusion center, urgent care clinic, or emergency department with a diagnosis warranting parenteral antimalarial or antirheumatic therapy where oral administration is not feasible. The patient may have nausea, vomiting, or malabsorption preventing oral chloroquine, or require rapid therapeutic levels for severe malaria prophylaxis or treatment in a traveler returning from an endemic area. A clinician (infectious disease specialist, emergency physician, or primary care provider) orders J0390 for an intramuscular or intravenous injection of chloroquine hydrochloride, up to 250 mg. Nursing documents medication administration, lot number, and site of injection; monitors for adverse reactions (e.g., gastrointestinal upset, pruritus, visual disturbances, QT prolongation) and vital signs for the observation period. Billing uses the HCPCS Level II code J0390; documentation includes indication, dose administered, route, date/time, and consent when required. Typical sites of service include outpatient infusion centers, emergency departments, hospital inpatient wards, and ambulatory clinics.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard use when no specific modifier applies for the service billed |